ribociclib and cabozantinib

ribociclib has been researched along with cabozantinib* in 1 studies

Other Studies

1 other study(ies) available for ribociclib and cabozantinib

Article	Year
Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15 Topics: Aminopyridines; Anilides; Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Pyridines	2017

Article

Year

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.

Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15

Topics: Aminopyridines; Anilides; Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Pyridines

2017